Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.70 CAD
Change Today 0.00 / 0.00%
Volume 0.0
As of 1:15 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

hemostemix inc (HEM) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/24/14 - C$1.25
52 Week Low
11/27/14 - C$0.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HEMOSTEMIX INC (HEM)

Related News

No related news articles were found.

hemostemix inc (HEM) Related Businessweek News

No Related Businessweek News Found

hemostemix inc (HEM) Details

Hemostemix Inc., a clinical-stage biotechnology company, focuses on developing, manufacturing, and commercializing blood-derived cell therapies to treat severe medical disorder. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, which that has completed phase II clinical trial used for the treatment of critical limb ischemia. It also produces various types of cells products, such as bone cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

hemostemix inc (HEM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$48.4K
Chief Financial Officer
Total Annual Compensation: C$34.7K
Executive Chairman and Corporate Secretary
Total Annual Compensation: --
Vice President of Research & Development and ...
Total Annual Compensation: C$135.0K
Compensation as of Fiscal Year 2014.

hemostemix inc (HEM) Key Developments

Hemostemix Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 02:30 PM

Hemostemix Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 02:30 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Elizabeth Wolffe, VP, Corporate Communications.

Hemostemix Inc. Announces Strategic Alliance Agreement with Hemostemix Asia, Inc

Hemostemix Inc. announced that it has executed a strategic alliance agreement with Hemostemix Asia Inc. The agreement covers a manufacturing and commercial license of the Hemostemix ACP-01 technology to HEMA for treating critical limb ischemia (CLI) patients in Taiwan, China, and South Korea. According to the agreement, HEMA plans to raise $5 million toward the implementation of their business plan and contribute up to 20 participants from three to five clinical sites in Taiwan to the ongoing Hemostemix phase-2 clinical trial for treating CLI. HEMA will also establish a manufacturing hub in Taiwan to serve the Asian market upon successful commercialization of ACP-01. The agreement further designates Hemostemix as an equity partner with 35% ownership in HEMA.

Hemostemix Inc. Announces International Phase-2 Clinical Trial for Critical Limb Ischemia

Hemostemix Inc. announced that in its international phase-2 clinical trial for critical limb ischemia (CLI): enrollment of its 20th patient. The double-blind, randomized, placebo-controlled trial currently recruits participants at six sites in Canada and South Africa under the same clinical protocol and will ultimately enroll approximately 100 participants with CLI. The trial studies the efficacy of the company's lead product, ACP-01, which uses angiogenic progenitor cells to combat the life-threatening complications of CLI. These proprietary cells are grown from a patient's own blood and, once injected into his or her diseased tissue, are able to support the formation of new blood vessels.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HEM:CN C$0.70 CAD 0.00

HEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HEM.
View Industry Companies

Industry Analysis


Industry Average

Valuation HEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 26.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HEMOSTEMIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at